IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

In chronic myeloid leukemia (CML), combination therapies with tyrosine kinase inhibitors (TKIs) aim to improve the achievement of deep molecular remission that would allow therapy discontinuation. IFN-α is one promising candidate, as it has long-lasting effects on both malignant and immune cells. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Huuhtanen, Jani, Ilander, Mette, Yadav, Bhagwan, Dufva, Olli M.J., Lähteenmäki, Hanna, Kasanen, Tiina, Klievink, Jay, Olsson-Strömberg, Ulla, Stentoft, Jesper, Richter, Johan, Koskenvesa, Perttu, Höglund, Martin, Söderlund, Stina, Dreimane, Arta, Porkka, Kimmo, Gedde-Dahl, Tobias, Gjertsen, Björn T., Stenke, Leif, Myhr-Eriksson, Kristina, Markevärn, Berit, Lübking, Anna, Dimitrijevic, Andreja, Udby, Lene, Bjerrum, Ole Weis, Hjorth-Hansen, Henrik, Mustjoki, Satu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433106/
https://www.ncbi.nlm.nih.gov/pubmed/36047494
http://dx.doi.org/10.1172/JCI152585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433106/
https://www.ncbi.nlm.nih.gov/pubmed/36047494
http://dx.doi.org/10.1172/JCI152585

Ejemplares similares